ORBIMED ADVISORS LLC

Q1 2022 13F-HR Holdings

Location
New York, NY
Holdings as of
3/31/2022
Date filed
5/16/2022
Form type
13F-HR
Num holdings
144
Total value ($000)
$6,167,262
Net value change ($000)
-1,611,193 (-20.7%)
New positions
9
Sold out positions
28
Turnover %
14.7%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 2/14/2022 Next filing: 8/15/2022 SEC filing

Snapshot: Change Analysis

Compared to Q4 2021
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
Biohaven Pharmaceutical Holding Co Ltd. 85,256 NEW
Global Blood Therapeutics, Inc. 54,613 NEW
ARGX 53,540 NEW
BMRN 50,927 67.0%
PFE 47,749 30.9%
Sierra Oncology, Inc. 30,854 96.1%
THC 29,584 121.1%
ISRG 26,851 20.0%
SIBN 19,746 38.6%
EVH 19,266 74.2%
Top Reduces (Value $000, Stocks/ETFs)
MRK -136,366 -100.0%
XBI -102,997 -91.1%
HCA -100,070 -100.0%
BMY -80,147 -29.6%
EWTX -77,812 -36.5%
Mirati Therapeutics, Inc. -75,179 -35.9%
SVA -72,700 -100.0%
ZBH -71,689 -100.0%
NTRA -67,152 -50.9%
PRLD -55,720 -44.6%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 7,834 (0.1% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type